Non-aqueous colonic purgative formulations
CA 2256896 C · Owner: Inkine Pharmaceutical Company, Inc. · Inventors: Krell, Robert D.; Williams, Taffy J.; Jacob, Leonard S.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Orally administered colonic purgative formulations and methods of their use for effecting partial or complete purgation of the colon in mammals the , formulations consisting of non-aqueous admixtures of a purgative salt selected from the group consisting of Mg3(PO4)2 MgHPO4, Mg(H2PO4)2, MgSO4, MgCl2, Na2SO4 sodium tartrate, potassium tartrate, magnesium tartrate and mixtures thereof, administered in tablet or capsule form in purgative effective concentrations. Preferred embodiments make use of at least one or more magnesium phosphate salts, more preferably dibasic magnesium phosphate; other preferred embodiments include the addition of binders dispersants and buffers , which do not …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 30, 1998 and granted November 19, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 30, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 30, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.